The Pharmacy Team: A Patient Safety Anchor in a Turbulent Sea

This educational activity focuses on the pharmacy team as the basis for incorporating standardization in concentrations and processes as the key to patient safety.

Parenteral Nutrition: Promoting an Umbrella of Safety 

This 1.5-hour educational activity will review safe practices for parenteral nutrition (PN) including dosing of lipid injectable emulsions (ILEs) to prevent essential fatty acid deficiency in patients, application of current guidelines to the safe care of patients receiving PN, and strategies for safe transitions of care in patients receiving PN.

Evolving Considerations for Prevention and Management of COVID 19—Let's Not Forget the Immunocompromised Patient!

This educational activity will present expert guidance for optimizing treatment and prevention of COVID-19 in the immunocompromised as well as strategies for reaching the target population.

This interprofessional educational activity uses a case-based approach to applying recent guidelines on Clostridioides difficile infection and the effects on quality-of-life.

This 1.5-hour activity uses a case-based approach to illustrate how to differentiate, recognize, and manage immune-related adverse events (irAEs) according to the most recent recommendations in national guidelines.

Adding It All Up: Cost-effectiveness Considerations for Ready-to-Administer IV Push Products 

This educational activity focuses on the cost-effectiveness considerations for ready-to-administer IV push products.

Existing and Emerging Clostridioides difficile Infection Therapies: Importance of Microbiome Restoration 

This educational activity will review existing and emerging therapeutic strategies for recurrent Clostridioides difficile infection and the logistical complexity of patient care.

JAK Inhibitors and the Changing Landscape for Atopic Dermatitis and Alopecia Areata  

This 1.5-hour educational activity provides an overview of current and emerging treatments for atopic dermatitis (AD) and alopecia areata (AA). Faculty address the role of the pharmacist in managing patients with AD and AA, including treating severe cases and monitoring for adverse effects.